Compare MFIN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIN | XBIT |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | 179 | N/A |
| Industry | Finance: Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 70.1M |
| IPO Year | N/A | 2015 |
| Metric | MFIN | XBIT |
|---|---|---|
| Price | $12.09 | $2.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 62.0K | 47.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.85 | $2.09 |
| 52 Week High | $12.23 | $3.44 |
| Indicator | MFIN | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.32 | 35.77 |
| Support Level | $9.39 | N/A |
| Resistance Level | N/A | $2.46 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 76.58 | 5.56 |
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.